LON:CLL - Cello Health Stock Price, News, & Analysis

Sign in or create an account to add this stock to your watchlist.
GBX 111.50 0.00 (0.00 %)
(As of 02/15/2019 04:00 PM ET)
Previous CloseGBX 111.50
Today's RangeGBX 111.50 - GBX 112.85
52-Week RangeGBX 115 - GBX 140
Volume5,343 shs
Average Volume46,452 shs
Market CapitalizationN/A
P/E RatioN/A
Dividend YieldN/A
Cello Health plc, together with its subsidiaries, provides marketing services in the United Kingdom, Rest of Europe, the United States, and internationally. It operates in two segments, Cello Health and Cello Signal. The Cello Health segment offers market research, consulting, and communications services principally to the pharmaceutical and healthcare clients. The Cello Signal segment provides market research and direct communications services principally to consumer-facing clients. Cello Health plc was incorporated in 2004 and is headquartered in London, the United Kingdom.

Receive CLL News and Ratings via Email

Sign-up to receive the latest news and ratings for CLL and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Marketing Services



Sales & Book Value

Annual SalesN/A



OptionableNot Optionable

Cello Health (LON:CLL) Frequently Asked Questions

What is Cello Health's stock symbol?

Cello Health trades on the London Stock Exchange (LON) under the ticker symbol "CLL."

How often does Cello Health pay dividends? What is the dividend yield for Cello Health?

Cello Health announced a dividend on Wednesday, September 19th. Stockholders of record on Thursday, October 4th will be paid a dividend of GBX 1.10 per share on Friday, November 2nd. This represents a dividend yield of 0.82%. The ex-dividend date is Thursday, October 4th. The official announcement can be viewed at this link. View Cello Health's Dividend History.

Has Cello Health been receiving favorable news coverage?

News coverage about CLL stock has been trending somewhat negative on Saturday, InfoTrie reports. The research firm ranks the sentiment of news coverage by monitoring more than six thousand news and blog sources in real-time. The firm ranks coverage of companies on a scale of -5 to 5, with scores closest to five being the most favorable. Cello Health earned a media sentiment score of -1.0 on InfoTrie's scale. They also assigned news coverage about the company a news buzz of 10.0 out of 10, indicating that recent news coverage is extremely likely to have an impact on the company's share price in the next several days.

Who are some of Cello Health's key competitors?

Who are Cello Health's key executives?

Cello Health's management team includes the folowing people:
  • Mr. Mark Scott, CEO & Exec. Director (Age 52)
  • Mr. Mark Bentley, Group Fin. Director, Company Sec. & Exec. Director (Age 47)
  • Mr. Stephen Highley, Group COO & Director
  • Mr. Owen Williams, Managing Partner
  • Mr. Vincent Nolan, Managing Partner

How do I buy shares of Cello Health?

Shares of CLL and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.

What is Cello Health's stock price today?

One share of CLL stock can currently be purchased for approximately GBX 111.50.

What is Cello Health's official website?

The official website for Cello Health is http://www.cellogroup.com/.

How can I contact Cello Health?

Cello Health's mailing address is 11-13 Charterhouse Buildings, LONDON, EC1M 7AP, United Kingdom. The company can be reached via phone at +44-20-78128460.

MarketBeat Community Rating for Cello Health (LON CLL)

Community Ranking:  3.5 out of 5 (star star star half star)
Outperform Votes:  315 (Vote Outperform)
Underperform Votes:  130 (Vote Underperform)
Total Votes:  445
MarketBeat's community ratings are surveys of what our community members think about Cello Health and other stocks. Vote "Outperform" if you believe CLL will outperform the S&P 500 over the long term. Vote "Underperform" if you believe CLL will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 2/16/2019 by MarketBeat.com Staff

Featured Article: Current Ratio

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel